HBW Insight speaks to Kerry Group's RDA director for digestive health, Mathieu Millette, about the opportunity represented by the global trend for GLP-1 agonists for consumer health.
First Insight survey with 1,267 US consumers showed 44% are more likely to try a private label product “marketed as a dupe of a high-end product.” Providers of OTC drugs as well as other medical products in US would tread on thin regulatory ice with the practice.
The European Commission’s Simplification Omnibus published July 8 is ‘step in right direction’ for streamlining processes and providing more legal certainty and predictability for regulations addressing cosmetics, says Cosmetics Europe.
HBW Insight speaks to Kerry Group's RDA director for digestive health, Mathieu Millette, about the opportunity represented by the global trend for GLP-1 agonists for consumer health.
